logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Panel Backs Merck Insomnia Drug Suvorexant, But At Lower Doses

The U.S. Food and Drug Administration advisory committee has Wednesday found clear evidence that healthcare giant Merck & Co., Inc.'s (MRK) blockbuster drug candidate suvorexant is quite effective in promoting sleep, but multiple safety issues call for lower doses.

The FDA's peripheral and central nervous system advisory committee reportedly agreed that the drug was generally safe and effective for treating sleep maintenance and latency. The panel voted 13-3, recommending lower starting doses of 15 mg for elderly and 20 mg for non-elderly.

The panel delivered a split recommendation, seven for and eight against, on the safety of the higher doses of the product. The safety issues from higher doses could seriously hamper Merck's attempt to market the new drug.

"Today's votes and discussion bring us one step closer to providing physicians with another option to help patients struggling with insomnia. We look forward to working with the FDA as the agency continues its review of our application," said Darryle Schoepp, senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories.

Suvorexant, a orexin receptor antagonist, will be a new class of insomnia drugs that works by blocking brain chemicals that keep people awake. It is indicated for patients with insomnia, a condition characterized by difficulty falling asleep and/or staying asleep. By temporarily blocking the actions of orexins, suvorexant helps to facilitate sleep.

Insomnia is a serious condition characterized by difficulties with sleep onset and/or maintenance that affects up to one-third of the adult population. Despite the availability of a number of medical treatments, it remains a significant medical problem. Persistent insomnia impacts patients directly through psychiatric and broader health-related risks, as well as society more generally through occupational, public safety, and economic aspects.

The world's second-biggest drugmaker said it anticipates FDA action on suvorexant over the next two months. The FDA will consider the panels recommendations and will take its advice into consideration, but is not bound by the panel's recommendations. However, it usually does.

The New Drug Application or NDA, for suvorexant was accepted in November 2012 for standard review by the U.S. FDA. The NDA was submitted by Merck Sharp & Dohme Corp. or MSD, as Merck is known outside the U.S. and Canada.

The company is continuing with plans to seek approval for suvorexant in other countries around the world.

MRK closed Wednesday's regular trading session at $46.71, down $0.62 or 1.31% on a volume of 42.63 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Google Maps introduced a new feature to share real-time location to a contact for 15 minutes to 3 days. The feature can be turned off at any time by the user. The tech leader believes that the feature will help friends meet up in a large park or a restaurant at a new location. One can open share... Instagram is expected to announce Wednesday that it has one million monthly active advertisers, representing a five-fold increase from a year ago. The photo and video app, owned by Facebook, had 500,000 monthly active advertisers in September 2016 and just 200,000 active advertisers a year ago. Offensive and extremist content appearing along with display ads has been creating headache for Google. There has been strong protests and boycott of ads by major advertisers and this has forced the company to expand their controls. The tech giant said the advertisers will have more say to display...
comments powered by Disqus
Follow RTT